

SynAct Pharma to participate in investor and partnering conferences

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced its attendance and presentations at multiple upcoming conferences in September and October 2026.

BioStock Investing in Life Science 2026, September 22, Stockholm, Sweden

Format: Company presentation

Presenting: Jeppe Øvlesen, Chief Executive Officer

Time: Tuesday, September 22, 11:55am CEST

Location: Main session

LSX Congress USA 2026, September 22-24, Boston, USA

Format: Panel discussion

Panel: From Seed to Scale: CEO Perspectives on Building Resilient Biotech Companies in Uncertain Markets

Panel Member: Mads Bjerregaard, Chief Business Officer

Time: Tuesday, September 22, 2026, 2:30pm - 3:00pm ET (Eastern Time, GMT-05:00)

Location: Biotech CEO Forum (Room 303)

Format: Company presentation

Presenting: Mads Bjerregaard, Chief Business Officer

Time: Wednesday, September 23, 4:30pm - 4:45pm ET

Location: Growth Showcase (Exhibition Hall)

Management will also be available to meet with investors and partners at the following conferences:

European MidCap Event 2026, September 30-October 1, Paris, France

Sachs Associates 26th Annual Biotech in Europe Forum, October 7- 8, Basel, Switzerland

Bio Japan, October 7-8, Yokohama, Japan

For further information, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

Investors and Media

Mary-Ann Chang, Cohesion Bureau

E-mail: synactpharma@cohesionbureau.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company pioneering pro-resolution therapies for inflammation through selective activation of the melanocortin system. Its lead asset, resomelagon (AP1189), is a once-daily oral, first-in-class biased agonist of the MC1 and MC3 melanocortin receptors, that has completed Phase 2b development in rheumatoid arthritis, and is in Phase 2 development as host-directed therapy to treat inflammation caused by infections, including respiratory viral infection and dengue. Behind resomelagon, SynAct is building a broad portfolio of oral small molecule and injectable peptide melanocortin agonists designed to induce anti-inflammatory pro-resolution activity, helping patients restore immune balance. For more information, please visit www.synactpharma.com.

Attachments

[SynAct Pharma to participate in investor and partnering conferences](#)